Article | September 8, 2021

Key Insights Into Overcoming mRNA Process Challenges

Source: Cytiva
iStock-1290118109-mrna-vaccine-covid-corona

When the COVID-19 pandemic began its outbreak in 2020, the biopharmaceutical industry began its work on developing a vaccine. The vaccines by Moderna and Pfizer-BioNTech using messenger RNA, or mRNA, emerged.

Due to challenges with distribution specificity and stability within the body, until now, mRNA has had a slow uptake in the industry. Scientific advances and an increase in resources and focus dedicated to mRNA research and development during the COVID-19 response have demonstrated its potential as a disruptive technology for the future of medicine.

However, there are still hurdles when it comes to efficient and effective process development of mRNA vaccines and therapies. Key areas and strategies can help alleviate bottlenecks in the growing market segment for mRNA.

VIEW THE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Pharmaceutical Online? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: